This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. VVOS, PETV, CODX, PAVM, SSKN, PSTV, ALUR, BTCY, ICU, and NUROShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Vivos Therapeutics (VVOS), PetVivo (PETV), Co-Diagnostics (CODX), PAVmed (PAVM), STRATA Skin Sciences (SSKN), Plus Therapeutics (PSTV), Allurion Technologies (ALUR), Biotricity (BTCY), SeaStar Medical (ICU), and NeuroMetrix (NURO). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Vivos Therapeutics PetVivo Co-Diagnostics PAVmed STRATA Skin Sciences Plus Therapeutics Allurion Technologies Biotricity SeaStar Medical NeuroMetrix Obalon Therapeutics (NASDAQ:OBLN) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership. Do institutionals and insiders believe in OBLN or VVOS? 18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend OBLN or VVOS? Vivos Therapeutics has a consensus price target of $6.10, indicating a potential upside of 131.94%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OBLN or VVOS more profitable? Vivos Therapeutics has a net margin of -86.19% compared to Obalon Therapeutics' net margin of -776.76%. Obalon Therapeutics' return on equity of -161.38% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Obalon Therapeutics-776.76% -161.38% -83.58% Vivos Therapeutics -86.19%-335.04%-93.58% Which has more volatility and risk, OBLN or VVOS? Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.31, indicating that its stock price is 631% more volatile than the S&P 500. Does the MarketBeat Community prefer OBLN or VVOS? Obalon Therapeutics received 229 more outperform votes than Vivos Therapeutics when rated by MarketBeat users. However, 60.71% of users gave Vivos Therapeutics an outperform vote while only 46.77% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformObalon TherapeuticsOutperform Votes24646.77% Underperform Votes28053.23% Vivos TherapeuticsOutperform Votes1760.71% Underperform Votes1139.29% Does the media favor OBLN or VVOS? In the previous week, Vivos Therapeutics had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for Vivos Therapeutics and 0 mentions for Obalon Therapeutics. Obalon Therapeutics' average media sentiment score of 0.00 equaled Vivos Therapeutics'average media sentiment score. Company Overall Sentiment Obalon Therapeutics Neutral Vivos Therapeutics Neutral Which has better valuation & earnings, OBLN or VVOS? Obalon Therapeutics has higher earnings, but lower revenue than Vivos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObalon Therapeutics$1.59M2.40-$12.33MN/AN/AVivos Therapeutics$15.03M1.03-$13.58M-$2.91-0.90 SummaryVivos Therapeutics beats Obalon Therapeutics on 9 of the 16 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.81M$4.29B$5.44B$7.80BDividend YieldN/A46.48%5.43%4.31%P/E Ratio-0.2830.2922.1418.40Price / Sales2.4052.50389.70101.30Price / CashN/A51.0838.2034.62Price / Book0.636.096.664.18Net Income-$12.33M$67.60M$3.21B$247.71M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$0.38-2.6%N/A+132.0%$3.81M$1.59M-0.282VVOSVivos Therapeutics1.3182 of 5 stars$2.20+4.8%$6.10+177.3%+5.4%$12.96M$15.03M-0.39160Gap DownPETVPetVivoN/A$0.52-6.4%N/A-34.0%$12.59M$1.05M-1.1620CODXCo-Diagnostics4.0999 of 5 stars$0.36+2.2%$1.00+181.5%-68.4%$11.93M$3.92M-0.26100Positive NewsGap DownPAVMPAVmed4.1308 of 5 stars$0.66-7.7%$19.50+2,876.6%-59.2%$11.20M$3.00M-0.1590Gap UpSSKNSTRATA Skin Sciences2.4438 of 5 stars$2.68+5.9%$6.00+123.9%-53.2%$11.18M$33.56M-1.01120Upcoming EarningsGap UpPSTVPlus Therapeutics1.7407 of 5 stars$0.64-2.7%$11.50+1,694.1%-47.3%$10.90M$4.91M-0.2520Gap DownALURAllurion Technologies1.9915 of 5 stars$2.26-3.4%$22.83+910.3%-95.1%$10.83M$32.11M-0.19501Gap DownBTCYBiotricityN/A$0.43+2.4%N/A-68.3%$10.71M$12.06M-0.4040Gap UpICUSeaStar Medical0.0904 of 5 stars$1.21-3.2%N/A-89.9%$10.55M$135,000.00-0.102NURONeuroMetrix0.4658 of 5 stars$4.32-2.3%N/A+0.8%$8.90M$3.03M-0.9420Gap Down Related Companies and Tools Related Companies VVOS Competitors PETV Competitors CODX Competitors PAVM Competitors SSKN Competitors PSTV Competitors ALUR Competitors BTCY Competitors ICU Competitors NURO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBLN Stock Free OBLN Stock Alerts